Abstract: A biological culture unit comprises a chamber body and a valve plate. The chamber body has defined therein a growth chamber and an aliquot chamber. The valve plate is disposed on the top surface of the chamber body and is movable to define selectable configurations of the biological culture unit for: (1) loading the growth chamber; (3) transferring an aliquot from the growth chamber to the aliquot chamber via a path defined within the biological culture unit in the transfer position; and (4) extracting the aliquot from the aliquot chamber. The selectable positions may further include (2) a growth position, and (5) a termination position for putting a termination agent into the growth and aliquot chambers. The valve plate may further include a neutralizer port that is aligned with the aliquot chamber in the loading position, for loading a neutralizing agent into the aliquot chamber.

Abstract: The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists.

Abstract: The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists.

Abstract: The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists.

Abstract: The present invention is directed to compounds, compositions and methods of treating pain, and derivatives that have potent analgetic activity. The compounds have the formula: ##STR1## wherein R.sup.1 is selected from H, lower alkyl, C.sub.3 -C.sub.9 cycloalkyl, acyl, C.sub.3 -C.sub.9 cycloalkylalkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, C.sub.3 -C.sub.8 cycloalkenyl C.sub.3 -C.sub.8 cycloalkynyl and phenyl; and wherein R is selected from cycloalkyl, aryl, heteroaryls (selected from the group consisting of pyridyl, thienyl, furanyl, imidazolyl, pyrazinyl, and pyrimidyl) or phenoxy and wherein said R groups can be substituted with hydroxyl, C.sub.1 -C.sub.6 lower alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.1 -C.sub.6 lower alkoxyl, halo, C.sub.1 -C.sub.6 haloalkyl, amino, C.sub.1 -C.sub.6 alkylamino and C.sub.2 -C.sub.10 dialkylamino, and sulfonamido or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides sulfur-containing xanthine derivatives which are 1,3-disubstituted with a C.sub.1 -C.sub.12 alkyl, which may be further substituted with a hydroxy, amino, or halo group, and are 8-substituted with either a cycloalkyl, furyl, thienyl, or substituted phenyl group. These derivatives possess increased selectivity or potency at adenosine receptors.

Abstract: The present invention is directed to compounds, compositions and methods of treating pain, and derivatives that have potent analgetic activity. The compounds have the formula: ##STR1## wherein R.sup.1 is selected from H, lower alkyl, C.sub.3 -C.sub.9 cycloalkyl, acyl, and C.sub.3 -C.sub.9 cycloalkylalkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, or C.sub.3 -C.sub.8 cycloalkenyl or C.sub.3 -C.sub.8 cycloalkynyl; and wherein R is selected from cycloalkyl, aryl, heteroaryls (selected from the group consisting of pyridyl, thienyl, furanyl, imidazolyl, pyrazinyl, and pyrimidyl) or phenoxy and wherein said R groups can be substituted with hydroxyl, C.sub.1 -C.sub.6 lower alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.1 -C.sub.6 lower alkoxyl, halo, C.sub.1 -C.sub.6 haloalkyl, amino, C.sub.1 -C.sub.6 alkylamino and C.sub.2 -C.sub.10 dialkylamino, and sulfonamido or a pharmaceutically acceptable salt thereof.

Abstract: This invention comprises a series of N.sup.6 -substituted adenosine analogues bearing functionalized chains for the covalent attachment to probes or solid supports. In these compounds coronary vasodilation in the open thorax dog model, typical of A.sub.2 -adenosine receptor agonists, is shown. The potency is modulated by distal structural changes in the chain, with the highest A.sub.2 -potency observed for two methylamides, a primary amine congener, and a biotin conjugate. These compounds have antihypertensive activity and certain components are charged and are excluded from crossing the blood-brain barrier.

Abstract: This application discloses probes for adenosine receptors which are functionalized congeners of the following compound: ##STR1## wherein R is --CH.sub.2 --C(O)--R' or ##STR2## These probes bind to A.sub.2 and A.sub.3 adenosine receptors and aid in quantifying and characterizing the receptors. The compounds may be labeled, for example with fluorescent compounds or radioactive compounds, or unlabeled.

Abstract: A functionalized congener approach to drugs acting at A.sub.1 and A.sub.2 adenosine receptor types is applicable to prodrug design. The prodrugs affect a more efficient delivery of the drug at the particular site of the body affected and take advantage of selective biochemical cleavages and alteration in distribution characteristics. In particular, kidney functions and lipid functions are stressed in the invention.

Abstract: Novel 8-phenylxanthines which are potent adenosine receptor antagonists.

Abstract: Certain functionalized cogeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity. Some of these analogs, containing a distal amino- or carboxylic-functionalized chain, are suitable for synthesis of amino acid conjugates. The compounds of this invention are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.

Abstract: Certain functionalized congeners of 1,3-dialkylxanthine exhibit high potency and selectivity as antagonists for A.sub.1 - and A.sub.2 -adenosine receptors and are suitable for attachment to probes, drug carriers, or solid supports. These derivatives are characterized by the presence of a phenyl at the 8 position para-substituted with a functionalized chain to provide high water solubility and high receptor affinity to such an extent that these compounds are suitable for use as antiallergenic, antiasthmatic, or cardiotonic drugs, central nervous system stimulants, and diuretics.

Abstract: Novel 8-phenylxanthines which are potent adenosine receptor antagonists.

Abstract: A method of forming an airfoil-shaped body is described which includes providing a core with cooling channels recessed into the surface thereof, affixing a calendered multilayer flexible mesh screen substrate to the surface of the core, applying braze alloy and brazing the assembly thereby filling completely the mesh screen pores and bonding further the mesh member substrate to the core, and applying an erosion-corrosion resistant layer over the brazed mesh member substrate completing the airfoil-shaped body.

Abstract: Airfoil-shaped bucket cores having grooves recessed into the surfaces thereof must be covered with an outer layer to provide the requisite aerodynamic and wearing surface and to define the cooling passages. In order to apply this outer layer by flame spraying (or comparable method of particle deposition), the core surface is first covered with a substrate layer. This substrate layer is provided with means by which later-applied surface coating material will be anchored in place. Thereafter, the outer material is applied (as by flame spraying, for example) and the surface thereof is ground and polished to dimension as may be needed.

Abstract: Stirrer construction adapted for both vertical and rotational movements is described for use in a fixed bed coal gasifier. Rabble arms projecting from a depending shaft are arranged as an upper and a lower set. The rabble arms in the lower set each present shear edges at and adjacent the tips thereof in order to be lowered into the ash zone, when desired, to break away the hard sintered masses that tend to develop along the wall there. Also, the lower set of rabble arms is designed for use in the combustion ("hot") zone to break up or loosen clinker formation with minimum damage to the ceramic liner in this portion of the gasifier. The rabble arms in the upper set are longer than the rabble arms in the lower set and extend closer to the wall of the gasifier being used both in order to center the stirrer shaft and to stir the upper regions of the coal bed.